eoadjuvant irinotecan and nedaplatin followed by radical hysterectomy for bulky stage Ib/II cervical cancer
Not Applicable
- Conditions
- stage IB2-IIb of uterine cervical cancer
- Registration Number
- JPRN-UMIN000021727
- Lead Sponsor
- Kansai Clinical Oncology Group; KCOG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Female
- Target Recruitment
- 68
Inclusion Criteria
Not provided
Exclusion Criteria
1) remarkable infection 2) severe complications (heart disease, incontorable diabetes) 3) with other malignancies 4) interstitial pneumonia 5) massive ascites 6) severe diarrhea 7) ileus 8) pregnant women 9) past history of severe allergy for drug
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2 year overall survival rate
- Secondary Outcome Measures
Name Time Method reponse rate of the neoadjuvant chemotherapy, adverse events rate